Menu: Home :: go to Journal :: switch to Russian :: switch to English
You are here: all Journals and Issues→ Journal→ Issue→ Article

Safety use of high doses of statins in nephrology

Annotation

Hyperlipidemia is a frequent companion to kidney disease, in some cases even reflecting the degree of activity of the renal process. Unfortunately, almost always the presence of lipid metabolism disorders of the renal patient impairs the prognosis both due to the acceleration of nephrosclerosis and due to the acceleration of atherosclerosis and the development of cardiovascular complications. On the basis of this, the article considers unique issues of statins administration in clinical practice of cardiologists and nephrologists, allowing to make a conclusion on efficiency in administration of high doses. We give dosages of drugs from the group of statins most frequently prescribed in the practice of a cardiologist, indicate modern aspects of treatment with statins, as well as side effects arising when administering this group of drugs, give data on statins assignment depending on values of tangle filtration rate (TFR) and analyze the results of randomized studies of JUPITER, PROVE-IT-TIMI, SPARCL, CNODES, allowing to conclude on possibilities of using different doses of statins in clinical practice. We also give recommendations for further administration of high doses of statins in treatment of dyslipidemias and give data on the change in the levels of low density lipoproteins (LDL) and high density lipoproteins (HDL) in the administration of statins

Keywords

nephrology, statins, hypolipidemic therapy, safety of application

Full-text in one file

Download

DOI

10.20310/2658-7688-2019-1-3-22-25

UDC

616.6

Pages

22-25

References

1. Yeshurun D., Gotto A.M. Southem Med J 1995; 88 (4): 379-391. 2. Knopp Rh.N Engl J Med 1999; 341: 498-511. 3. Gupta EK, Ito MK. Product Preseribing Information. Heart Dis 202; 4: 399-409. 4. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49: 37-45. 5. De Jager DJ, Grootendorst DC, Jager KJ, van Dyk PC, Tomas LMJ, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JFM, Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302: 1782-1789. 6. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16:3748-3754. 7. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016

Received

2019-09-15

Section of issue

Clinical medicine

Для корректной работы сайта используйте один из современных браузеров. Например, Firefox 55, Chrome 60 или более новые.